Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BLUE

bluebird bio's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, bluebird bio (NASDAQ:BLUE) posted sales of $1.61 million. Earnings were up 28.49%, but bluebird bio still reported an overall loss of $155.05 million.

Expert Ratings For bluebird bio

Expert Ratings For bluebird bio

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:

Why Bluebird Bio Shares Are Tumbling Today

Why Bluebird Bio Shares Are Tumbling Today

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies

1 … 12 13 14 15

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play